Systemic Sclerosis

Clinical Research Institute of Michigan – Shores Rheumatology
Main: 586-598-3329
Study Coordinator: Amelia Laurence 586-598-3329 X 201
Study Coordinator: Latrece Keaton 586-598-3329 X 202

  • Indication: Systemic Sclerosis
  • Enrollment Status: Pre-Enrollment
  • Protocol: 1305-0052 “Veranda”
  • Drug: Nerandomilast
  • Sponsor: Boehringer Ingelheim International GmbH
  • Description: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc).

Returning Member? Please login to check membership status!